TNNI3 Antibody

中文名稱：

TNNI3兔多克隆抗體
貨號：

CSB-PA07936A0Rb
規格：

￥440
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) TNNI3 Polyclonal antibody
Uniprot No.：

P19429
基因名：

TNNI3
別名：

cardiac muscle antibody; Cardiac troponin I antibody; cardiomyopathy; dilated 2A (autosomal recessive) antibody; Cardiomyopathy; familial hypertrophic; 7; included antibody; CMD1FF antibody; CMD2A antibody; CMH7 antibody; cTnI antibody; Familial hypertrophic cardiomyopathy 7 antibody; MGC116817 antibody; RCM1 antibody; Tn1 antibody; Tni antibody; TNN I3 antibody; TNNC 1 antibody; TNNC1 antibody; TNNI3 antibody; TNNI3_HUMAN antibody; Troponin I antibody; Troponin I cardiac antibody; Troponin I cardiac muscle antibody; Troponin I cardiac muscle isoform antibody; Troponin I type 3 cardiac antibody; troponin I; cardiac 3 antibody; TroponinI antibody; Ttroponin I type 3 (cardiac) antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Troponin I, cardiac muscle protein (2-210AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，TNNI3 Antibody (CSB-PA07936A0Rb)，的標記方式是Non-conjugated。對于TNNI3 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA07936B0Rb	TNNI3 Antibody, HRP conjugated	ELISA
FITC	CSB-PA07936C0Rb	TNNI3 Antibody, FITC conjugated
Biotin	CSB-PA07936D0Rb	TNNI3 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA
Protocols：

ELISA Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.
基因功能參考文獻：
1. Data show that the incident atrial fibrillation (AF) occurrence group had similar baseline troponin I (TnI) levels, but higher troponin T (TnT) levels [Review and Meta-Analysis]. PMID: 29631448
2. Studies indicate that in patients with end-stage renal disease (ESRD), elevation of cardiac-specific troponin T (cTnT) was more frequent than elevation of troponin I (cTnI) [Review]. PMID: 28545334
3. the frequency of h-FABP positivity among acute myocardial infarction patients was higher than that of hs-TnI, which would have missed six of them; however, hs-TnI area under curve was superior to that of h-FABP. PMID: 28650717
4. Reversible Covalent Reaction of Levosimendan with Cardiac Troponin C in Vitro and in Situ. PMID: 29558109
5. The QT interval has a strong positive linear correlation with cardiac troponin-I levels in Non-ST-elevation myocardial infarction. PMID: 28366473
6. Apelin-12 influences troponin I levels in the acute phase of STEMI, whereas during the non-acute phase, low apelin levels were associated with a high rate of MACE. PMID: 28728608
7. In clinical stable patients without known cardiovascular disease, a thorough chest-pain history in combination with hs-TnI testing can identify a significant low-risk group. PMID: 28031149
8. Study showed that in patients who underwent liver transplantation elevation of preoperative high-sensitivity cardiac troponin I level was associated with 1-year mortality and 30-day mortality. PMID: 28542299
9. Serial measurement of troponin I revealed a persistent elevation in patients with diabetes mellitus type 2. PMID: 28246236
10. Plasma troponin C1 (cTnI) is biomarker of choice for diagnosing acute myocardial infarction (AMI) because of its high specificity as biomarker for damage to myocardial tissue. Data suggest the "best cut-off" for plasma cTnI is 0.014 micrograms/L in AMI. These studies were conducted in emergency department of a university hospital in Italy using point-of-care testing in patients presenting with chest pain, ages 18-101. PMID: 28377153
11. NT-proBNP and hs-cTnI levels were higher in systemic sclerosis patients than controls. Both NT-proBNP and hs-cTnI were associated with the presence of echocardiographic abnormalities. PMID: 27601074
12. value of cTnI level assessed 24 hours post-surgery was a reliable predictor of death following liver transplantation with optimal cut-off value of 0.215 ng/mL. The surgery time was the most important predictor of cTnI elevation. PMID: 28455997
13. cTnI levels are common in Fabry disease patients, reflecting cardiac involvement. PMID: 27322070
14. Report novel troponin I rule-out value below the upper reference limit for acute myocardial infarction. PMID: 27067356
15. cTnI determined in hemodynamically stable patients with suspected AMI and wide QRS complex using optimized diagnostic thresholds improves rule-in and rule-out with respect to presence of a significant obstructive CAD PMID: 27148734
16. 83 preterm infants with Bronchopulmonary dysplasia born <28-wk gestation and still inpatients at 36-wk corrected age received an echocardiogram and blood tests of B-type natriuretic peptide (BNP), troponin I, and YKL-40. PMID: 27760764
17. Serum cardiac troponin I was increased in septic patients with myocardial depression compared to those without myocardial depression. PMID: 27238916
18. Elevated BNP and hs-cTnI after kidney transplantation identify candidates for targeted risk reduction. PMID: 26910333
19. These perturbed biophysical and biochemical myofilament properties are likely to significantly contribute to the diastolic cardiac pump dysfunction that is seen in patients suffering from a restrictive cardiomyopathy that is associated with the cTnI R145W mutation. PMID: 27557662
20. epigenetic modification caused cTnI expression decrease is one of the possible causes that result in a reduced cTnI level and diastolic dysfunction in older mouse hearts PMID: 27184165
21. Among hospitalized patients with cardiac troponin I values above 30 ng/L, the majority will have myocardial injury. Cardiac nonischemic conditions are associated with very high troponin concentrations, but the outcome is rather good. In contrast, myocardial injury related to noncardiac or multiple conditions carries a very poor long-term prognosis. PMID: 26763756
22. troponin I carboxy terminal mobile domain and linker sequence has a role in regulating cardiac contraction PMID: 26971468
23. the last 5 C-terminal residues of cTnI influence the binding of cTnI with cTnC and cTnT and affect the Ca(2+) dependence of filament sliding PMID: 26919894
24. Study found that N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I are independently associated with incident dementia and NT-proBNP with incident Alzheimer's disease PMID: 28039523
25. The clones were selected using microtiter plate coated with human cardiac troponin I (hcTnI). Product of hybridoma cells that bind with high affinity to human cardiac troponin I were selected PMID: 27556913
26. Sex, age, and systolic blood pressure belong to the strongest determinants of hs-cTnI in healthy adults. PMID: 27535138
27. This review summarizes the recent proteomic data on aminoacid sequences of cTnT and cTnI in various species, as well as selected analytical characteristics of human cardiac troponin high-sensitivity assays PMID: 26876101
28. In stable coronary artery disease patients successfully treated with PCI, pre-procedural cTnI levels, in the upper limits of the normal range, are associated with hard cardiac endpoints. PMID: 25405803
29. Calcium channel blockers and adrenergic beta antagonists reduced hs-TnI levels significantly both at rest and during exercise in atrial fibrillation patients/. PMID: 27142292
30. Compromised interactions of K206I with actin and hcTnC may lead to impaired relaxation and HCM. PMID: 26553696
31. hsTnI at the time of presentation followed by early advanced coronary CTA assessment improves the risk stratification and diagnostic accuracy for acute coronary syndromes. PMID: 26476506
32. These findings showed that a double heterozygous mutation in the TNNI3 gene is involved in the pathogenesis of hypertrophic cardiomyopathy via haploinsufficiency. PMID: 26506446
33. The incidence of adverse cardiovascular events was significantly higher in patients with troponin elevation after carotid endarterectomy, which was mainly attributable to silent non-ST segment elevation MIs that occurred in the early post-operative phase. PMID: 26553374
34. Four novel missense variants were identified in TNNI3. PMID: 26169204
35. Letter/Case Report: acute decompensated heart failure with troponin I elevation in hereditary hemochromatosis. PMID: 25916738
36. In this pilot study, the addition of CACS to hsTnI improves the identification of low-risk subjects in whom CTA might be avoided. PMID: 26049777
37. Exclusion of acute myocardial infarction 2h after presentation in emergency patients with possible acute coronary syndrome can be achieved using hs-cTnT or hs-cTnI assays. PMID: 24316100
38. Hybrid coronary revascularization is associated with lower postoperative cTn release, compared with off-pump coronary artery bypass surgery. PMID: 25217621
39. Carotid endarterectomy is followed by a high incidence of asymptomatic cTnI increase that is associated with late cardiac events. PMID: 25601178
40. mutations underlying restrictive cardiomyopathy all marked by right-sided cardiac manifestations in South African patients PMID: 25940119
41. Circulating levels of sensitive cTnI and NT-proBNP are related to LV function and infarct size in patients with stable CAD after revascularization. PMID: 25788439
42. Serum TnI detected significant myocardial necrosis in a majority of patients with chronic HF due to LVSD and when measured serially, provided independent risk information for poor CV outcomes and deleterious LV remodeling. PMID: 25777344
43. The elevation of Tn I after PCI in patients with normal initial level is more significant predictor of early (30-day) mortality compared to later (within 12 months) mortality. PMID: 25617100
44. AF patients both without and with CAD showed similar cTnI concentrations at admission. A second validation of cTnI is mandatory for all patients. PMID: 25653186
45. cardiac troponin T or troponin I compared to creatine kinase in patients with revascularized acute myocardial infarction PMID: 25381953
46. Even a single elevated Troponin I value increased the risk of myocardial infarction. PMID: 25195101
47. Abbott high-sensitivity cardiac-TnI levels in a total of 3314 Korean patients with chest pain, were determined. PMID: 25887868
48. Absolute delta performed significantly better than relative delta at all time intervals to measure changes in troponin I for early diagnosis of myocardial infarction. PMID: 25261587
49. The high accordance with LGE, reflecting cardiac dysfunction, suggests that cTNI-elevation can be a useful laboratory parameter for assessing myocardial damage in FD. PMID: 24626231
50. Using an overall 99th percentile for cTnI does not appear to increase the prevalence of myocardial injury or lead to further hospital admissions from the emergency department. PMID: 26185217
顯示更多

收起更多
相關疾?。?/div>
Cardiomyopathy, familial hypertrophic 7 (CMH7); Cardiomyopathy, familial restrictive 1 (RCM1); Cardiomyopathy, dilated 2A (CMD2A); Cardiomyopathy, dilated 1FF (CMD1FF)
蛋白家族：

Troponin I family
數據庫鏈接：

HGNC: 11947

OMIM: 115210

KEGG: hsa:7137

STRING: 9606.ENSP00000341838

UniGene: Hs.709179

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human